Monitorización de instrumentación avanzada para docencia en red

[EN] Due to university internationalization, learning’s concept is not linked to a specific geographical place. This document describes the methods used to visualize the laboratory’s instruments (oscilloscope Tektronix TDS 210 and the generator Agilent 33120A) monitored remotely. Being able to generalize to any instrument that has an interface for remote connection regardless of the type of bus technology.[ES] Debido a la internacionalización universitaria, el concepto aprendizaje no está vinculado a un lugar geográfico específico. Este documento describe los métodos utilizados para visualizar en el laboratorio los instrumentos (osciloscopio Tektronix TDS 210 y el generador Agilent 33120A) monitorizados de forma remota. Pudiéndose generalizar a cualquier instrumento que tenga interfaz para conexión remota independientemente del tipo de tecnología bus.Talens Felis, JB.; Pelegrí Sebastiá, J.; Ibáñez Sabater, FJ.; Sogorb, T. (2018). Monitorización de instrumentación avanzada para docencia en red. En IN-RED 2018. IV Congreso Nacional de Innovación Educativa y Docencia en Red. Editorial Universitat Politècnica de València. 256-269. https://doi.org/10.4995/INRED2018.2018.8731OCS25626

Revisión del tratamiento actual de los sofocos inducidos por deprivación androgénica en el carcinoma prostático

Dada la mayor incidencia, prevalencia y supervivencia del carcinoma prostático en la actualidad, el manejo de los sofocos derivados de su tratamiento con análogos LH-RH ha de ser muy tenido en cuenta. El tratamiento más utilizado y a la vez el más eficaz, es la sustitución hormonal pero este tipo de terapia no esta exenta de riesgos. Hoy por hoy es factible el abordaje de los sofocos de estos pacientes mediante un variado arsenal terapéutico en el cual el tratamiento hormonal puede quedar relegado al último lugar, dado el riesgo de recidiva o progresión tumoral al tratarse de un tumor hormonosensible. El objetivo de este trabajo es revisar los tratamientos utilizados actualmente y las medidas higiénico-dietéticas que pueden ayudar a disminuir la sintomatología. Se revisarán tanto los tratamientos hormonales como los no hormonales basados en su evidencia científica. Fármacos como los nuevos antidepresivos, la gabapentina y la clonidina podrían jugar un papel destacado en el manejo. Sus mecanismos de actuación aunque dispares, se enmarcan en el complejo sistema de retroalimentación ejercido por los niveles de hormonas sexuales sobre la secreción hipotalámica de noradrenalina, causa principal en la génesis de los sofocos

LDR brachytherapy offers superior tumor control to single-fraction HDR prostate brachytherapy: A prospective study

[Purpose]: To compare the clinical outcomes of single-fraction high-dose-rate (HDR) brachytherapy and single-fraction low-dose-rate (LDR) brachytherapy as the sole treatment for primary prostate cancer. [Material and Methods]: A quasi-randomized study that allocated, from March 2008 to February 2012, 129 low and intermediate risk prostate cancer patients to one single-fraction HDR of 19 Gy (61 patients) or to a 145 Gy 125I LDR permanent implant (68 patients. Biochemical relapse-free survival (bRFS) and overall survival (OS) were compared using the Kaplan–Meier method and Cox regression analysis. [Results]: After a median follow-up of 72 months in the HDR group, 26 patients relapsed, and after a median follow-up of 84 months in the LDR group, 7 patients relapsed (p < 0.0001). The 5-year bRFS was significantly better for the LDR group than for the HDR group (93.7% and 61.1%, respectively) (p < 0.0001). The 5-year OS also was significantly better in the LDR group (95.5% vs. 89.9%) (p = 0.0436). [Conclusions]: Permanent LDR prostate implant brachytherapy offers better clinical outcomes than single-fraction HDR for prostate cancer.Peer reviewe

Identifying the main sources of Silicate in coastal waters of the southern Gulf of Valencia (Western Mediterranean Sea)

[EN] Silicon is a major nutrient for siliceous primary producers, which can become a potential limiting nutrient in oligotrophic areas. Most of the silicon inputs to the marine environment come from continental discharges, from both superficial and ground waters. This study analyses the main sources of silicon and their dynamics along the southernmost 43 km of shoreline in the Gulf of Valencia (Western Mediterranean Sea). The salinity and silicate concentration in the different compartments (springs, freshwater wells, beach groundwater, surf zone and coastal waters) in this coastal area were determined. In addition, chlorophyll a and phytoplankton community were analyzed in the surf zone and coastal waters. Silicate concentrations in freshwater wells ranged between 130 and 150 mu M, whereas concentrations of this nutrient declined to 49 mu M in freshwater-seawater mixture transects. At the same time, there was a positive gradient in silicate for both freshwater and coastal waters southward. An amount of 18.7 t of dissolved silicate was estimated in the nearest first kilometre nearest to the coastline, 6 t of this silicate belonged to the background sea level. On the other hand, the sum of the main rivers in the area supplies 1.6 t of dissolved silicate per day. This implies that a large amount of the remaining 11.1 t must derive from submarine groundwater discharges, which would thus represent 59% of the coastal dissolved silicate budget. Overall, it is suggested that a subterranean transport pathway must contribute considerably to silicate concentrations throughout this zone, which is characterized as permeable. (c) 2017 Institute of Oceanology of the Polish Academy of Sciences. Production and hosting by Elsevier Sp. z o.o.The authors acknowledge the financial support for this study from the CNPq (Brazil - Grant 303672/2013-7). We are very grateful for the valuable comments of anonymous reviewers on previous versions of the manuscript.Sospedra, J.; Niencheski, LFH.; Falco, S.; Andrade, C.; Attisano, K.; Rodilla, M. (2018). Identifying the main sources of Silicate in coastal waters of the southern Gulf of Valencia (Western Mediterranean Sea). Oceanologia. 60(1):52-64. https://doi.org/10.1016/j.oceano.2017.07.004S526460

Palbociclib radiosensitizes colon and lung cancer cell lines in a p53-dependent manner

Resumen del trabajo presentado al 1st PhD Research Symposium in Health Sciences and Biomedicine, celebrado en la Universidad Autónoma de Madrid el 18 de mayo de 2018.Study supported by Fundación Leticia Castillejo Castillo.Peer reviewe

P53 pathway is a major determinant in the radiosensitizing effect of Palbociclib: Implication in cancer therapy

Targeting cell cycle has become one of the major challenges in cancer therapy, being Palbociclib, a CDK4/6 inhibitor, an excellent example. Recently, it has been reported that Palbociclib could be a novel radiosensitizer agent. In an attempt to clarify the molecular basis of this effect we have used cell lines from colorectal (HT29, HCT116) lung (A549, H1299) and breast cancer (MCF-7). Our results indicate that the presence of a p53 wild type is strictly required for Palbociclib to exert its radiosensitizing effect, independently of the inhibitory effect exerted on CDK4/6. In fact, abrogation of p53 in cells with functional p53 blocks the radiosensitizing effect of Palbociclib. Moreover, no radiosensitizing effect is observed in cells with non-functional p53, but restoration of p53 function promotes radiosensitivity associated to Palbociclib. Furthermore, the presence of Palbociclib blocks the transcriptional activity of p53 in an ATM-dependent-fashion after ionizing radiation exposure, as the blockage of p21/WAF1 expression demonstrates. These observations are a proof of concept for a more selective therapy, based on the combination of CDK4/6 inhibition and radiotherapy, which would only benefit to those patients with a functional p53 pathway.This work was supported by grants from Fundación Leticia Castillejo Castillo, and Ministerio de Economía y Competitividad (SAF2015-64215-R) to RSP and MJRH. OR has a contract for accessing the Spanish System of Science, Technology and Innovation (SECTI) funded by the University of Castilla-La Mancha and received partial support from the European Social Fund through its Operative Program for Castilla-La Mancha (2007–2013). RSP and MJRH Research Institute, and the work carried out in their laboratory, received partial support from the European Community through the Regional Development Funding Program (FEDER).Peer reviewe

p38ß (MAPK11) mediates gemcitabine-associated radiosensitivity in sarcoma experimental models

[Background and purpose]: Gemcitabine is an antitumour agent currently used in the treatment of several types of cancer with known properties as a radiosensitizer. p38MAPK signalling pathway has been shown to be a major determinant in the cellular response to gemcitabine in different experimental models. However, the molecular mechanism implicated in gemcitabine-associated radiosensitivity remains unknown.[Materials and methods]: The human sarcoma cell lines A673 and HT1080, and a mouse cell line derived from a 3-methylcholanthrene induced sarcoma were used as experimental models. Modulation of p38MAPKs was performed by pharmacological approaches (SB203580) and genetic interference using lentiviral vectors coding for specific shRNAs. Viability was assessed by MTT. Gene expression was evaluated by western blot and RT-qPCR. Induction of apoptosis was monitored by caspase 3/7 activity. Response to ionizing radiation was evaluated by clonogenic assays.[Results]: Our data demonstrate that chemical inhibition of p38MAPK signalling pathway blocks gemcitabine radiosensitizing potential. Genetic interference of MAPK14 (p38¿), the most abundantly expressed and best characterized p38MAPK, despite promoting resistance to gemcitabine, it does not affect its radiosensitizing potential. Interestingly, specific knockdown of MAPK11 (p38ß) induces a total loss of the radiosensitivity associated to gemcitabine, as well as a marked increase in the resistance to the drug.[Conclusion]: The present work identifies p38ß as a major determinant of the radiosensitizing potential of gemcitabine without implication of p38¿, suggesting that p38ß status should be analysed in those cases in which gemcitabine is combined with ionizing radiation.This work was supported by grants from Fundación Leticia Castillejo Castillo, Ministerio de Ciencia, Innovación y Universidades (MCIU), Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (FEDER) (RTI2018-094093-B-I00) to RSP and MJRH. OR holds a contract for accessing the Spanish System of Science, Technology and Innovation (SECTI) funded by the University of Castilla-La Mancha (UCLM) and received partial support from the European Social Fund (FSE) through its Operative Program for Castilla-La Mancha (2007–2013). RSP and MJRH’s Research Institute, and the work carried out in their laboratory, received partial support from the European Community through the FEDER. RSP is a researcher of CSIC temporarily adscribed to UCLM